Portal de Periódicos da CAPES

TRANSURETHRAL RESECTION WITH PERIOPERATIVE INSTILLATION OF INTERFERON-alpha OR EPIRUBICIN FOR THE PROPHYLAXIS OF RECURRENT PRIMARY SUPERFICIAL BLADDER CANCER: A PROSPECTIVE RANDOMIZED MULTICENTER STUDY-FINNBLADDER III

1999; Lippincott Williams & Wilkins; Volume: 161; Issue: 4 Linguagem: Inglês

10.1016/s0022-5347(01)61609-4

1527-3792

Pertti Rajala, Tapani Liukkonen, Mika Raitanen, Erkki Rintala, Eero Kaasinen, M Helle, O Lukkarinen,

Urological Disorders and Treatments

No AccessJournal of UrologyClinical Urology: Original Articles1 Apr 1999TRANSURETHRAL RESECTION WITH PERIOPERATIVE INSTILLATION OF INTERFERON-alpha OR EPIRUBICIN FOR THE PROPHYLAXIS OF RECURRENT PRIMARY SUPERFICIAL BLADDER CANCER: A PROSPECTIVE RANDOMIZED MULTICENTER STUDY-FINNBLADDER III PERTTI RAJALA, TAPANI LIUKKONEN, MIKA RAITANEN, ERKKI RINTALA, EERO KAASINEN, MARKKU HELLE, and OLAVI LUKKARINEN PERTTI RAJALAPERTTI RAJALA , TAPANI LIUKKONENTAPANI LIUKKONEN , MIKA RAITANENMIKA RAITANEN , ERKKI RINTALAERKKI RINTALA , EERO KAASINENEERO KAASINEN , MARKKU HELLEMARKKU HELLE , and OLAVI LUKKARINENOLAVI LUKKARINEN View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)61609-4AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the efficacy of single dose of interferon or epirubicin administered immediately after transurethral resection compared with transurethral resection only on the recurrence of primary (not recurrent) superficial bladder cancer. Materials and Methods: A total of 283 patients with stages Ta to T1 primary superficial, grades 1 to 3 bladder cancer was randomized into study groups 1-transurethral resection only, 2-transurethral resection plus 50 million units interferon-alpha 2b and 3-transurethral resection plus 100 mg. epirubicin. Eligible for final analysis were 200 patients, including 66 in group 1, 66 in group 2 and 68 in group 3. Patients were followed with cystoscopy every 3 months for 2 years or until the initial recurrence. Results: Group 3 had the most favorable outcome, since 45 of the 68 patients (66%) were without recurrence after 2 years compared to 24 of the 66 (37%) in group 2 and 26 of the 66 (40%) in group 1 (log rank test p <0.001). Side effects were mostly mild and transient, and no differences were found among the groups. Conclusions: A single 100 mg. dose of epirubicin given intravesically immediately after transurethral resection is safe, and significantly decreases the recurrence of primary superficial bladder cancer. A 50 million unit dose of interferon-alpha 2b is well tolerated but it has no effect on recurrence as a single dose. The long-term effect of this treatment remains to be studied. References 1 : Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J. Urol.1982; 127: 250. Link, Google Scholar 2 : The biology and treatment of superficial bladder cancer. J. Clin. Oncol.1984; 2: 505. Crossref, Medline, Google Scholar 3 : Urothelial susceptibility to tumor cell implantation. Influence of cauterization. Cancer1980; 46: 1158. Google Scholar 4 : Identification of p53 gene mutations in bladder cancers and urine samples. Science1990; 252: 706. Google Scholar 5 : Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Brit. J. Urol.1976; 48: 55. Google Scholar 6 : A controlled trial of single dose intravesical adriamycin in superficial bladder tumours. Brit. J. Urol.1981; 53: 585. Google Scholar 7 : Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J. Urol.1983; 129: 505. Link, Google Scholar 8 : Single-dose intravesical epodyl after TUR of Ta TCC bladder carcinoma. World J. Urol.1983; 1: 89. Crossref, Google Scholar 9 : Members of the EORTC-GU Group: A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J. Urol.1993; 149: 749. Google Scholar 10 : Cytostatic effect of different strains of bacillus Calmette-Guerin on human bladder cancer cells in vitro alone and in combination with mitomycin C and interferon alpha. Urol. Res.1992; 20: 215. Google Scholar 11 : A controlled study of intravesical epirubicin with or without alpha2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Brit. J. Urol.1995; 76: 697. Google Scholar 12 : TNM Classification of Malignant Tumours. In: . Geneva: World Health Organization1978: 113. Google Scholar 13 : Histological Typing of Urinary Bladder Tumours. International Histological Classification of Tumours. Geneva: World Health Organization1973. Google Scholar 14 The effect of intravesical thiotepa on tumour recurrence after endoscopic treatment of newly diagnosed superficial bladder cancer. A further report with long-term follow-up of a Medical Research Council randomized trial. Medical Research Council Working Party on Urological Cancer, Subgroup on Superficial Bladder Cancer. Brit. J. Urol.1994; 73: 632. Google Scholar 15 : The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of followup. J. Urol.1996; 155: 1233. Link, Google Scholar From the Divisions of Urology, Turku University Hospital, Mikkeli Central Hospital, Tampere University Hospital, Helsinki City Hospital, Hyvinkaa District Hospital and Mikkeli Central Hospital and Department of Pathology, Oulu University Hospital, Turku, FinlandThe Finnbladder Group; Members: M. Ala-Opas and K. Tuhkanen, Kuopio University Hospital: O. Alfthan, Eira Hospital; T. Forsell, Kymenlaakso Central Hospital, Kotka; P. Granbacka, Pietarsaari District Hospital; O. Hynninen, K. Lehtoranta and M. Talja, Paijat-Hame Central Hospital, Lahti; K. Jauhiainen and T. Liukkonen, Mikkeli Central Hospital; H. Juusela, District Hospital of Jorvi, Espoo; P. Kemppainen, Central Hospital of Kainuu; Kajaani and H. Korhonen, Satakunta Central Hospital, Pori; T. Lahdes-Vasama, S. Rannikko and M. Ruutu, Helsinki University Central Hospital; J. Hakkinen, P. Hallstrom, M. Kontturi, O. Lukkarinen and M. Raitanen, Oulu University Hospital; M. Nurmi and P. Rajala, Turku University Central Hospital; J. Ottelin, Kemi Central Hospital; P. Pellinen, Kokkola Central Hospital; J. Permi and V.-M. Puolakka, Lappeenranta Central Hospital; E. Rintala, Helsinki City Hospital; T. L. Tammela and H. Tainio, Tampere University Hospital, and R. Usenius, Jyvaskyla Central Hospital.© 1999 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byChou R, Selph S, Buckley D, Fu R, Griffin J, Grusing S and Gore J (2016) Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-AnalysisJournal of Urology, VOL. 197, NO. 5, (1189-1199), Online publication date: 1-May-2017.Berrum-Svennung I, Granfors T, Jahnson S, Boman H and Holmäng S (2007) A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small RecurrencesJournal of Urology, VOL. 179, NO. 1, (101-106), Online publication date: 1-Jan-2008.SYLVESTER R, OOSTERLINCK W and van der MEIJDEN A (2018) A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, VOL. 171, NO. 6 Part 1, (2186-2190), Online publication date: 1-Jun-2004.Rajala P, Kaasinen E, Raitanen M, Liukkonen T and Rintala E (2018) Perioperative Single Dose Instillation of Epirubicin or Interferon-α After Transurethral Resection for The Prophylaxis of Primary Superficial Bladder Cancer Recurrence: A Prospective Randomized Multicenter Study—Finnbladder III Long-Term ResultsJournal of Urology, VOL. 168, NO. 3, (981-985), Online publication date: 1-Sep-2002.BÖHLE A, JURCZOK A, ARDELT P, WULF T, ULMER A, JOCHAM D and BRANDAU S (2018) INHIBITION OF BLADDER CARCINOMA CELL ADHESION BY OLIGOPEPTIDE COMBINATIONS IN VITRO AND IN VIVOJournal of Urology, VOL. 167, NO. 1, (357-363), Online publication date: 1-Jan-2002. Volume 161Issue 4April 1999Page: 1133-1136 Advertisement Copyright & Permissions© 1999 by American Urological Association, Inc.Metrics Author Information PERTTI RAJALA More articles by this author TAPANI LIUKKONEN More articles by this author MIKA RAITANEN More articles by this author ERKKI RINTALA More articles by this author EERO KAASINEN More articles by this author MARKKU HELLE More articles by this author OLAVI LUKKARINEN More articles by this author Expand All Advertisement PDF downloadLoading ...